Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Foreign Drug Makers Increased Market Share to Over 60% among Top 20 Makers in 2017
March 9, 2018
- Torii’s Futhan to Get 43.4% Price Cut in April, Urinorm 24.6%: Top 5 Product Survey
March 8, 2018
- Insomnia Drug Lemborexant Hits PIII Goals in Sleep Disorders: Eisai
March 8, 2018
- US FDA Approves Latuda for Pediatric Use in Bipolar I Depression: Sumitomo Dainippon
March 8, 2018
- Yoshikazu Aoki Named as New Asahi Kasei Pharma President
March 8, 2018
- Mid-Sized Japan Makers to Take Heaviest Hit from April Price Cut, Bigger Peers See Smaller Reductions: Jiho Survey
March 7, 2018
- Average NHI Price Reduction Rate of 12.8% for 3 Major Generic Makers: Jiho Tally
March 7, 2018
- Astellas, Tottori Univ. Pair Up to Develop, Commercialize Immunostimulating Gene Loading Oncolytic Virus
March 7, 2018
- Takeda Consumer Healthcare President Sugimoto to Step Down following 1 Year Stint since Firm’s Inception
March 7, 2018
- Alcon Pharma Reorganizes Marketing System to Boost Market Shares of Major Products including Lucentis
March 5, 2018
- Japan Ethical Drug Sales Slip 1.0% in 2017, Harvoni Drops Out of Top 10 List: IQVIA
March 2, 2018
- World’s 1st Commercial Manufacturing Plant for Allogeneic iPSC Therapies Completed: Sumitomo Dainippon
March 2, 2018
- Canaglu Launched in Taiwan: Mitsubishi Tanabe
March 2, 2018
- Galderma Completes Transfer of Japan Rozex Rights to Maruho
March 2, 2018
- Pfizer to Copromote Effexor SR with Sumitomo Dainippon
March 2, 2018
- Daiichi Sankyo US Subsidiary to Restructure Sales Unit with 280 Job Culls, Anticipating Launch of Oncology Agents
March 2, 2018
- Despite Solid Mainstays, Pfizer Japan’s FY2017 Sales Down 6.6% on LLPs
March 2, 2018
- Valixa’s Pediatric Indication Filed for CMV Infection in Organ Transplant
March 1, 2018
- Kaken Grants Rights for Psoriasis Drug Candidate to Valeant
March 1, 2018
- MSD Seeks Japan Approval of Broad-Spectrum Antibiotic
March 1, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…